Suggested Remit: To appraise the clinical and cost effectiveness of semaglutide within its marketing authorisation for treating type 2 diabetes.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- None selected
- Process:
- STA Standard
- ID number:
- 1450
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 April 2019 | Following the scoping exercise this topic was not referred to NICE for a Technology Appraisal. It was agreed the topic would be incorporated in clinical guideline update (NICE guideline 28). The block scoping report containing this topic is published here; https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/block-scoping-reports (Batch 64) |
| 22 November 2018 - 20 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual